INTRODUCTION: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are increasingly utilized in the treatment of diabetes mellitus as well as therapeutic extra-glycemic effects. However, there are still concerns over complications such as amputation events, given the results from the Canagliflozin Cardiovascular Assessment Study (CANVAS) trial. Hence, we conducted a systematic review and meta-analysis of randomized-controlled trials to investigate the effect of SGLT2 inhibitors on amputation events. METHODS: Four electronic databases (PubMed, Embase, Cochrane, and SCOPUS) were searched on November 21, 2020, for articles published from January 1, 2000, up to November 21, 2020, for studies that examined the effect of SGLT2 inhibitors on amputation events. Random-effect pair-wise meta-analysis for hazard ratios and fixed-effect Peto odds ratio meta-analysis were utilized to summarize the studies. RESULTS: A total of 15 randomized-controlled trials were included with a combined cohort of 63,716 patients. We demonstrated that there was no significant difference in amputation events across different types of SGLT2 inhibitors, different baseline populations, and different duration of SGLT2 inhibitor use. DISCUSSION/ CONCLUSIONS: In this meta-analysis, SGLT2 inhibitors were not associated with a significant difference in amputation events.
INTRODUCTION: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are increasingly utilized in the treatment of diabetes mellitus as well as therapeutic extra-glycemic effects. However, there are still concerns over complications such as amputation events, given the results from the Canagliflozin Cardiovascular Assessment Study (CANVAS) trial. Hence, we conducted a systematic review and meta-analysis of randomized-controlled trials to investigate the effect of SGLT2 inhibitors on amputation events. METHODS: Four electronic databases (PubMed, Embase, Cochrane, and SCOPUS) were searched on November 21, 2020, for articles published from January 1, 2000, up to November 21, 2020, for studies that examined the effect of SGLT2 inhibitors on amputation events. Random-effect pair-wise meta-analysis for hazard ratios and fixed-effect Peto odds ratio meta-analysis were utilized to summarize the studies. RESULTS: A total of 15 randomized-controlled trials were included with a combined cohort of 63,716 patients. We demonstrated that there was no significant difference in amputation events across different types of SGLT2 inhibitors, different baseline populations, and different duration of SGLT2 inhibitor use. DISCUSSION/ CONCLUSIONS: In this meta-analysis, SGLT2 inhibitors were not associated with a significant difference in amputation events.
Authors: Willem D Rinkel; Jacky Luiten; Jelle van Dongen; Bram Kuppens; Johan W Van Neck; Suzanne Polinder; Manuel Castro Cabezas; J Henk Coert Journal: Diabetes Res Clin Pract Date: 2017-07-29 Impact factor: 5.602
Authors: Stephen D Wiviott; Itamar Raz; Marc P Bonaca; Ofri Mosenzon; Eri T Kato; Avivit Cahn; Michael G Silverman; Thomas A Zelniker; Julia F Kuder; Sabina A Murphy; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Christian T Ruff; Ingrid A M Gause-Nilsson; Martin Fredriksson; Peter A Johansson; Anna-Maria Langkilde; Marc S Sabatine Journal: N Engl J Med Date: 2018-11-10 Impact factor: 91.245
Authors: Michael E Nassif; Sheryl L Windsor; Fengming Tang; Yevgeniy Khariton; Mansoor Husain; Silvio E Inzucchi; Darren K McGuire; Bertram Pitt; Benjamin M Scirica; Bethany Austin; Mark H Drazner; Michael W Fong; Michael M Givertz; Robert A Gordon; Rita Jermyn; Stuart D Katz; Sumant Lamba; David E Lanfear; Shane J LaRue; JoAnn Lindenfeld; Michael Malone; Kenneth Margulies; Robert J Mentz; R Kannan Mutharasan; Michael Pursley; Guillermo Umpierrez; Mikhail Kosiborod Journal: Circulation Date: 2019-09-16 Impact factor: 29.690
Authors: Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews Journal: N Engl J Med Date: 2017-06-12 Impact factor: 91.245
Authors: Carol Pollock; Bergur Stefánsson; Daniel Reyner; Peter Rossing; C David Sjöström; David C Wheeler; Anna Maria Langkilde; Hiddo J L Heerspink Journal: Lancet Diabetes Endocrinol Date: 2019-04-13 Impact factor: 32.069
Authors: Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher Journal: BMJ Date: 2009-07-21
Authors: Clare Arnott; Yuli Huang; Brendon L Neuen; Gian Luca Di Tanna; Christopher P Cannon; Richard Oh; Robert Edwards; Mary Kavalam; Norman Rosenthal; Vlado Perkovic; Meg J Jardine; Kenneth Mahaffey; Bruce Neal Journal: Diabetes Obes Metab Date: 2020-06-24 Impact factor: 6.577